Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Nigora Rasulova"'
Publikováno v:
Diagnostics, Vol 5, Iss 3, Pp 358-368 (2015)
Radium-223-dichloride (223RaCl2) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for the treatment skeletal metastases of hormone-refractory prostate cancer. The current treatment regimen is based on s
Externí odkaz:
https://doaj.org/article/9a1fce6d366a4634862cd13efeb290a0
Publikováno v:
Asia Oceania Journal of Nuclear Medicine and Biology, Vol 2, Iss 2, Pp 131-134 (2014)
Radionuclide therapy is widely used as an effective modality in the management of bone pain. The main indication for this treatment is symptomatic bone metastases, confirmed by bone scintigraphy. We present a case of small cell lung cancer (SCLC) sta
Externí odkaz:
https://doaj.org/article/fb29873ec9824f97bc70d7334a3fa481
Publikováno v:
6th International Conference on Radiopharmaceutical Therapy (ICRT 2021) Abstracts.
Publikováno v:
Nuclear medicine communications. 42(1)
Objectives Tc-sestamibi is the current radiopharmaceutical of choice for the localization of hyperactive lesions of the parathyroid glands in patients with hyperparathyroidism. However, there are multiple factors that adversely affect the accumulatio
Autor:
Qaisar Hussain Siraj, Nigora Rasulova
Publikováno v:
Radionuclide Parathyroid Imaging ISBN: 9783030173500
The parathyroid glands are responsible for calcium homeostasis through secretion of the parathyroid hormone. These glands were the last organ to be recognised in humans. There are normally two pairs of parathyroid glands, superior and inferior, locat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11210e5a36efc74fdf0d72daa10c1b2d
https://doi.org/10.1007/978-3-030-17351-7_1
https://doi.org/10.1007/978-3-030-17351-7_1
Autor:
Qaisar Hussain Siraj, Nigora Rasulova
Publikováno v:
Radionuclide Parathyroid Imaging ISBN: 9783030173500
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5799b7536dec927449ff415090319fc8
https://doi.org/10.1007/978-3-030-17351-7_2
https://doi.org/10.1007/978-3-030-17351-7_2
Publikováno v:
Diagnostics, Vol 5, Iss 3, Pp 358-368 (2015)
Diagnostics
Diagnostics
Radium-223-dichloride (223RaCl2) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for the treatment skeletal metastases of hormone-refractory prostate cancer. The current treatment regimen is based on s
Publikováno v:
Journal of Diagnostic Imaging in Therapy. 1:59-72
Autor:
Nigora Rasulova, Marat Khodjibekov, Sh. Sh. Sagdullaev, Dauranbek Arybzhanov, Vladimir Lyubshin, Valery Krylov
Publikováno v:
World Journal of Nuclear Medicine, Vol 12, Iss 1, Pp 14-18 (2013)
World Journal of Nuclear Medicine
World Journal of Nuclear Medicine
While bisphosphonates are indicated for prevention of skeletal-related events, radionuclide therapy is widely used for treatment of painful bone metastases. Combined radionuclide therapy with bisphosphonates has demonstrated improved effectiveness in
Publikováno v:
World Journal of Nuclear Medicine, Vol 12, Iss 1, Pp 19-23 (2013)
World Journal of Nuclear Medicine
World Journal of Nuclear Medicine
Breast and prostate cancer have a propensity to metastasize to bones and cause osteolysis and abnormal new bone formation. Metastases locally disrupt normal bone remodeling. Although metastases from prostate cancer have been classified as osteoblasti